August 19, 2021
PAR-19-171 - Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
National Institute of Neurological Disorders and Stroke (NINDS)
The purpose of this notice is to inform interested applicants of a change to the Key Dates for Funding Opportunity Announcement (FOA) PAR-19-171 "Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)". This FOA has been extended by one additional council round. The dates have been modified to add the following New Application Due Date: February 18, 2022, Revision, Resubmission Date: March 18, 2022, and AIDS Application Due Date: May 7, 2022.
The following section of PAR-19-171 has been modified as follows:
Currently Reads:
Part 1. Overview
Key Dates:
Application Due Date(s) |
New applications: March 29, 2019; June 18, 2019; October 18, 2019; February 19, 2020; June 18, 2020; October 14, 2020; February 18, 2021; June 18, 2021; October 14, 2021, by 5:00PM local time of the applicant organization. Resubmission or, Revision applications: April 30, 2019; July 18, 2019; November 14, 2019; March 18, 2020; July 14, 2020; November 18, 2020, March 18, 2021; July 14, 2021; November 18, 2021, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
AIDS Application Due Date(s) |
Standard AIDS dates apply, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. The first AIDS due date for this FOA is May 7, 2018. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
Scientific Merit Review | July 2019, November 2019, March 2020, July 2020, November 2020, March 2021, July 2021, November 2021, March 2022 |
Advisory Council Review | October 2019, January 2020, May 2020, October 2020, January 2021, May 2021, October 2021, January 2022, May 2022 |
Earliest Start Date | November 2019, February 2020, June 2020, November 2020, February 2021, June 2021, November 2021, February 2022, June 2022 |
Expiration Date | January 8, 2022 |
Modified to Read (changes shown in bold italics):
Part 1. Overview
Key Dates:
Application Due Date(s) |
New applications: March 29, 2019; June 18, 2019; October 18, 2019; February 19, 2020; June 18, 2020; October 14, 2020; February 18, 2021; June 18, 2021; October 14, 2021; February 18, 2022, by 5:00PM local time of the applicant organization. Resubmission or, Revision applications: April 30, 2019; July 18, 2019; November 14, 2019; March 18, 2020; July 14, 2020; November 18, 2020, March 18, 2021; July 14, 2021; November 18, 2021; March 18, 2022, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
AIDS Application Due Date(s) |
Standard AIDS dates apply, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. The first AIDS due date for this FOA is May 7, 2018. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
Scientific Merit Review | July 2019, November 2019, March 2020, July 2020, November 2020, March 2021, July 2021, November 2021, March 2022, July 2022 |
Advisory Council Review | October 2019, January 2020, May 2020, October 2020, January 2021, May 2021, October 2021, January 2022, May 2022, October 2022 |
Earliest Start Date | November 2019, February 2020, June 2020, November 2020, February 2021, June 2021, November 2021, February 2022, June 2022, November 2022 |
Expiration Date | May 8, 2022 |
All other aspects of this FOA remain unchanged.
Adam L. Hartman, MD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9135
E-mail: [email protected]